2 weeks Ago By ABMN Staff
KLP Kapitalforvaltning AS acquired a new position in shares of Xenon Pharmaceuticals Inc. ( NASDAQ:XENE – Free Report ) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 12,800 shares of the biopharmaceutical company’s stock, valued at approximately $502,000.
Other hedge funds have also modified their holdings of the company. Janus Henderson Group PLC boosted its holdings in shares of Xenon Pharmaceuticals by 144.2% in the third quarter.
Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company’s stock worth $100,506,000 after buying an additional 1,507,135 shares during the period. State Street Corp grew its position in Xenon Pharmaceuticals by 13.2% during the 3rd quarter.
State Street Corp now owns 279,513 shares of the biopharmaceutical company’s stock worth $11,004,000 after purchasing an additional 32,701 shares in the last quarter. Two Sigma Advisers LP grew its position in Xenon Pharmaceuticals by 31.0% during the 3rd quarter.
Two Sigma Advisers LP now owns 273,700 shares of the biopharmaceutical company’s stock worth $10,776,000 after purchasing an additional 64,800 shares in the last quarter. Wellington Management Group LLP raised its stake in Xenon Pharmaceuticals by 0.4% during the 3rd quarter.
Wellington Management Group LLP now owns 3,843,447 shares of the biopharmaceutical company’s stock valued at $151,317,000 after purchasing an additional 15,226 shares during the period. Finally, Y Intercept Hong Kong Ltd lifted its holdings in shares of Xenon Pharmaceuticals by 68.8% in the third quarter.
Y Intercept Hong Kong Ltd now owns 24,557 shares of the biopharmaceutical company’s stock valued at $967,000 after purchasing an additional 10,007 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling In related news, CEO Ian Mortimer sold 16,315 shares of the firm’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $40.50, for a total value of $660,757.
50. Following the transaction, the chief executive officer now directly owns 31,302 shares of the company’s stock, valued at approximately $1,267,731. This trade represents a 34.
26 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link . 5.
52% of the stock is currently owned by corporate insiders. Xenon Pharmaceuticals Stock Performance Xenon Pharmaceuticals ( NASDAQ:XENE – Get Free Report ) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.
84) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.05.
As a group, sell-side analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.
Analyst Ratings Changes A number of research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft began coverage on Xenon Pharmaceuticals in a report on Tuesday, February 11th. They set a “buy” rating and a $67.
00 price target on the stock. Royal Bank of Canada reiterated an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. StockNews.
com raised shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 29th. William Blair reaffirmed an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. Finally, HC Wainwright reiterated a “buy” rating and issued a $53.
00 target price on shares of Xenon Pharmaceuticals in a research report on Monday, February 24th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.
38. Check Out Our Latest Stock Analysis on Xenon Pharmaceuticals Xenon Pharmaceuticals Profile ( Free Report ) Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Featured Articles Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc. ( NASDAQ:XENE – Free Report ).
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
_0.jpg?itok=yAIF6nFK)
